The Company raised $85 million in Series B financing led by Janus Henderson, EQT Nexus, Hillhouse and British Business Bank. In addition to the Series B, Tenpoint entered into a $150 million non-dilutive senior secured term loan facility with Hercules Capital. This financing reflects their confidence in YUVEZZI, a new differentiated option for millions of people living with the daily frustration and challenges of presbyopia," said Henric Bjarke, Chief Executive Officer of Tenpoint Therapeutics. "With our strengthened balance sheet, we are excited to launch YUVEZZI in early Q2." By understanding real-world needs and partnering with eye care professionals, Tenpoint is working to bring innovation to the aging eye.